6 results about "Abnormal proteins" patented technology

The present invention provides a polypeptide that specifically recognizes structurally abnormal proteins generated in mammals due to misfolding or the like, and an agent for detecting or reducing structurally abnormal proteins that uses the polypeptide. The present invention relates to an agent for detecting structurally abnormal proteins, comprising as an active ingredient a polypeptide having structurally abnormal proteins-binding site which is a polypeptide consisting of the amino acid sequence represented by SEQ ID NO:2, or a polypeptide consisting of an amino acid sequence having 90% or more sequence identity with the amino acid sequence and having binding activity to structurally abnormal proteins, and an agent for reducing structurally abnormal proteins comprising as an active ingredient a polypeptide containing the structurally abnormal protein binding site and a ubiquitin ligase active site.

Bipartite molecules comprising a peptide affinity moiety and at least one charged moiety and uses thereof in reducing formation of abnormal protein aggregate and treating diseases associated with such abnormal protein aggregate, including neurodegenerative disease characterized by formation of protein aggregates.

Described herein are polypeptide useful for identifying compound for modulating aberrant protein condensates. The polypeptide comprise a condensate-modulating protein, a first biomarker polypeptide, a barcoding biomarker polypeptide. When inside a cell, the non-natural polypeptide exist as multiple fragments, including a first fragment comprising the condensate-modulating protein and the first biomarker polypeptide, and a second fragment comprising the barcoding biomarker polypeptide. The barcoding biomarker polypeptide is uniquely associated with and identifies the cell expressing associated condensate-modulating protein. Also described is a polynucleotide encoding the non-natural polypeptide, a library of the polynucleotide, and a method of identifying compound for modulating aberrant protein condensates using the non-natural polypeptide, the construct, and / or the library.

The invention discloses a preparation method of an Iars1 gene knockout zebrafish model, which comprises the following steps: mixing sgRNA fragments and Cas9 protein, injecting a mixed solution into zebrafish fertilized eggs in 1-2 cell stages through micro-injection, and obtaining Iars1 gene edited individuals after the fertilized eggs are hatched and cultured; after genotype identification, family screening and continuous breeding, the stably inherited Iars1 gene knockout zebrafish mutant strain is obtained. According to the invention, a zebrafish Iars1 gene is subjected to targeted editing by adopting a CRISPR / Cas9 technology, a zebrafish model carrying deletion mutation is obtained, and a stably inherited mutant is obtained through molecular identification. The model constructed by the invention can be used for researching early development abnormality related to Iars1 function deficiency, and an experimental model can be provided for evaluating early nutrition utilization abnormality, protein translation related abnormality and candidate interveners. The construction method is reliable, the model phenotype is clear, and the method has good research and application prospects.

Provided is an agent for inhibiting abnormal protein aggregate accumulation or an agent for inhibiting the uptake of an abnormal protein into a neuron, particularly an agent for preventing or treating a disease associated with accumulation of abnormal protein aggregates, in which the agent contains an RGMa inhibiting substance.